AMA Wades Deeper Into Rx-Price Transparency Debate With New Position

Patients should be told when co-pays are more than drug cash-prices, according to the American Medical Association. By adopting the policy at the AMA's annual interim meeting, physicians waded further into the debate over drug price transparency. “As spikes in prescription drug prices occur without justification, the American Medical Association believes we need more transparency to protect patients from drug price gouging and manipulation,” AMA President-elect Barbara McAneny said. The pharmacy benefit manager practice that AMA targets is one of...